Australian Research Team Identifies Ivermectin Zaps COVID-19 in Cell Cultures

Australian Health Ministry Funds more Clinical Trials Targeting COVID-19

Researchers from Monash University’s Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity at Royal Melbourne Hospital recently published the results of a study revealing that Ivermectin, an approved anti-parasitic drug available worldwide, may actually treat against SARS-CoV-2 when applied to an infected cell culture. In the study, Ivermectin materially reduced SARS-CoV-2 viral RNA material in the cell culture by 93% just after 24 hours and by 99.8% 48 hours later. This represents a 5000X reduction in COVID-19 RNA, suggesting that the drug was reducing “essentially all viral material.”

The Down Under team suggests that Ivermectin, previously known to have anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2) with a single addition to vero-hSLAM cells in 2 hours post infection with SARS-CoV-2 able to impact a 5000X reduction in viral RNA at 48 hours. The team Down Under suggests Ivermectin be seriously investigated for possible use in humans.

What is Ivermectin?

The medication is used to treat many types of parasite infestations such as head lice, scabies, river blindness and many other conditions...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee